⌘K
Loading ticker…
As of 2026-08-24, Seres Therapeutics, Inc. (MCRB) has a 3-month relative strength percentile of 9 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 30. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.3%, relative volume 1.16×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MCRB is in a stage 4 downtrend, week 7. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -18.0% / -54.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
MCRB is held by 4 ETFs as of May 2026. Top owner: AVUV at 0.00% weight, $274K notional. Top 3 carry $540K.
Held by 9 ETFs · $3M across latest filings · largest weight 0.03% (IWC).
Top 4 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | 0.00% | $274K | — |
| SCHASchwab U.S. Small-Cap ETF | 0.00% | $227K | — |
| AVSC | 0.00% | $39K | — |
| AVUSAvantis U.S. Equity ETF | 0.00% | $7K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MCRB Jan avg: -4.92% median: -1.03% win: 50% σ: 9.72% n: 4 2022-04-12 → 2026-07-31 | MCRB Feb avg: -14.59% median: -8.91% win: 25% σ: 18.50% n: 4 2022-04-12 → 2026-07-31 | MCRB Mar avg: -6.53% median: -3.16% win: 50% σ: 18.91% n: 4 2022-04-12 → 2026-07-31 | MCRB Apr avg: -12.25% median: -16.91% win: 20% σ: 23.55% n: 5 2022-04-12 → 2026-07-31 | MCRB May avg: -11.99% median: -0.68% win: 40% σ: 17.45% n: 5 2022-04-12 → 2026-07-31 | MCRB Jun avg: 9.03% median: 7.79% win: 60% σ: 31.05% n: 5 2022-04-12 → 2026-07-31 | MCRB Jul avg: 18.99% median: 19.82% win: 80% σ: 45.13% n: 5 2022-04-12 → 2026-07-31 | MCRB Aug avg: -2.66% median: -1.61% win: 50% σ: 36.95% n: 4 2022-04-12 → 2026-07-31 (current) | MCRB Sep avg: 3.41% median: 9.88% win: 75% σ: 24.95% n: 4 2022-04-12 → 2026-07-31 | MCRB Oct avg: -6.84% median: -14.84% win: 25% σ: 31.50% n: 4 2022-04-12 → 2026-07-31 | MCRB Nov avg: -6.85% median: -7.45% win: 50% σ: 26.25% n: 4 2022-04-12 → 2026-07-31 | MCRB Dec avg: -2.93% median: -14.52% win: 25% σ: 25.07% n: 4 2022-04-12 → 2026-07-31 |